LONDON (Alliance News) - IXICO PLC said Monday it has signed a new GBP1 million contract with a pharmaceutical company.
The neuroscience-focused digital technologies company said the contract, with one of its existing clients, will last three years.
Under the agreement, IXICO will provide its technology-enabled imaging services in a study of people with early manifest Huntington's disease to observe the natural progression of the disease.
IXICO has been involved in studies of the disease since 2007.
Chief Executive Officer Giulio Cerroni said: "Today's announcement continues IXICO's successful track record in providing neuroimaging clinical trial services for Huntington's disease, representing our third new contract in this therapeutic area in the current financial year."
"I am delighted that we continue to win new business with existing clients which I believe demonstrates the value placed by our customers on the unique combination of technologies and scientific expertise that we provide."
IXICO shares were trading lower 3.7% at 30.33 pence.
Ixico (IXI)